IQVIA (NYSE:IQV) Stock Price Expected to Rise, Morgan Stanley Analyst Says

IQVIA (NYSE:IQV) had its price target lifted by Morgan Stanley from $245.00 to $250.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical research company’s stock. Morgan Stanley’s price target indicates a potential upside of 26.49% from the stock’s previous close.

IQV has been the subject of several other reports. Truist Financial reaffirmed a “buy” rating and set a $263.00 target price (up from $261.00) on shares of IQVIA in a research report on Monday. Bank of America lowered their price objective on IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $248.00 price objective (down from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $251.67.

IQVIA Stock Performance

NYSE:IQV opened at $197.64 on Tuesday. The stock’s 50-day moving average is $200.77 and its 200-day moving average is $218.81. IQVIA has a 1-year low of $187.62 and a 1-year high of $261.73. The company has a current ratio of 0.84, a quick ratio of 0.81 and a debt-to-equity ratio of 2.12. The stock has a market cap of $35.87 billion, a P/E ratio of 26.35, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Equities research analysts anticipate that IQVIA will post 10.81 earnings per share for the current year.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl bought 1,275 shares of IQVIA stock in a transaction dated Tuesday, December 3rd. The stock was bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at approximately $255,739.50. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Hedge funds have recently made changes to their positions in the business. Capital Performance Advisors LLP purchased a new stake in IQVIA during the third quarter worth about $27,000. Synergy Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the last quarter. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $44,000. Finally, Zions Bancorporation N.A. lifted its stake in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.